Latest European Expansion News

Electro Optic Systems (ASX:EOS) reports sustained demand driven by global conflicts, launches MARSS business in Europe, and updates 2026 revenue outlook with base business guidance of $240m to $270m.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

OncoSil Medical has secured a pivotal ethics committee approval in Italy, reclassifying its OSPRItaly registry and enabling a streamlined procurement process that could double the number of authorised hospitals using its OncoSil™ device by mid-2027.

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Smart Parking Limited grew its ANPR sites by 17% in Q3 FY26 and increased parking breach notices by 19%, leveraging acquisitions and AI technology to expand across Europe and New Zealand.

Regener8 Resources has formalised its acquisition of the Srebrenica North polymetallic project in Bosnia and Herzegovina, setting the stage for a maiden exploration program targeting high-grade silver and base metals in a prolific European mining district.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Adslot Ltd achieved positive net operating cash flow in Q3 FY26 while trimming its workforce by nearly a third to sharpen focus on its Symphony and Webfirm units. The company is navigating declining marketplace revenues and preparing for a key contract renewal with Group M.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Redivium Limited advances its recapitalisation efforts and project development despite ASX suspension, withdrawing its European Green Bond and exploring new UK site options.